Anticoagulant therapy during cardiopulmonary bypass

Area of Science:

• Cardiovascular Medicine
• Hematology
• Surgical Innovation

Background:

• Cardiac surgery, particularly with cardiopulmonary bypass (CPB), induces a unique prothrombotic and hemostatic-altering environment.
• This complex milieu significantly increases the risk of both thrombotic and hemorrhagic complications in patients.

Purpose of the Study:

• To highlight the critical role of anticoagulant therapy during CPB.
• To underscore the necessity of preventing thrombin generation and its associated adverse effects.
• To address the limitations of current anticoagulation standards and advocate for improved therapeutic strategies.

Main Methods:

• Review of existing literature on anticoagulation in cardiac surgery and CPB.
• Analysis of the prothrombotic and hemostatic challenges posed by CPB.
• Discussion of the limitations and safety profile of unfractionated heparin.

Main Results:

• The environment during CPB is exceptionally conducive to both thrombosis and hemorrhage.
• Unfractionated heparin has been the standard anticoagulant for over 50 years.
• Limitations and safety concerns associated with unfractionated heparin are significant.

Conclusions:

• Effective anticoagulation is paramount during CPB to mitigate thrombotic and vascular complications.
• The limitations and safety profile of unfractionated heparin necessitate the development of superior anticoagulant therapies.
• Further research and development are crucial for safer and more effective anticoagulation strategies in cardiac surgery.